Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Nowak

Showing results (351-360 of 441) with videos related to

Pageof 45
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 22, 2013
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaAnna K Nowak, Chris Brown, Michael J Millward, et al.
Lung Cancer (Amsterdam, Netherlands)|January 6, 2020
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesotheliomaWei-Sen Lam, Jenette Creaney, Fred K Chen, et al.
Asia-Pacific Journal of Clinical Oncology|November 9, 2017
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trialKathryn M Field, Greg Fitt, Mark A Rosenthal, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2021
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is usedVanessa S Fear, Catherine A Forbes, Samuel A Neeve, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2024
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural MesotheliomaAnna K Nowak, Dorothy J Giroux, Megan Eisele, et al.
BMC Health Services Research|May 28, 2021
Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocolJennifer Philip, Roslyn Le Gautier, Anna Collins, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2016
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for MesotheliomaValerie W Rusch, Kari Chansky, Hedy L Kindler, et al.
Journal of Crohn'S & Colitis|February 25, 2022
Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2Jan K Nowak, Alex T Adams, Rahul Kalla, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 29, 2017
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs)U Ronellenfitsch, M Schwarzbach, R Hofheinz, et al.
Frontiers in Immunology|May 31, 2022
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive CombinationsNicola Principe, Wayne J Aston, Danika E Hope, et al.
Pageof 45

Showing results (351-360 of 441) with videos related to

Sort By:
Pageof 45
Lung Cancer (Amsterdam, Netherlands)|June 22, 2013
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaAnna K Nowak, Chris Brown, Michael J Millward, et al.
Lung Cancer (Amsterdam, Netherlands)|January 6, 2020
A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesotheliomaWei-Sen Lam, Jenette Creaney, Fred K Chen, et al.
Asia-Pacific Journal of Clinical Oncology|November 9, 2017
Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trialKathryn M Field, Greg Fitt, Mark A Rosenthal, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2021
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is usedVanessa S Fear, Catherine A Forbes, Samuel A Neeve, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2024
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Proposal for Revision of the TNM Stage Groupings in the Forthcoming (Ninth) Edition of the TNM Classification for Pleural MesotheliomaAnna K Nowak, Dorothy J Giroux, Megan Eisele, et al.
BMC Health Services Research|May 28, 2021
Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocolJennifer Philip, Roslyn Le Gautier, Anna Collins, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2016
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for MesotheliomaValerie W Rusch, Kari Chansky, Hedy L Kindler, et al.
Journal of Crohn'S & Colitis|February 25, 2022
Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2Jan K Nowak, Alex T Adams, Rahul Kalla, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 29, 2017
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs)U Ronellenfitsch, M Schwarzbach, R Hofheinz, et al.
Frontiers in Immunology|May 31, 2022
Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive CombinationsNicola Principe, Wayne J Aston, Danika E Hope, et al.
Pageof 45